19 December 2018
Visiongain has launched a new pharma report Pharma Leader Series: Top 20 Asthma & COPD Companies 2019-2029: Company Overview, Marketed Products, Product Pipeline, Revenues, Forecast.
The asthma and COPD market benefits from increasing prevalence of respiratory diseases, coupled with the high economic cost of those diseases. The industry will also have more biologics and synthetic anti-inflammatory agents for both asthma and COPD, as companies look to identify and offer treatments for multiple patient sub-groups.
The lead analyst of the report commented "Developments in treatment are expected to continue as new drugs and emerging technologies become more widely available. This may include personalised treatments for certain types of asthma not responding to the stepwise approach of the Global Initiative for Asthma (GINA) guidelines and treatments tailored to the specific composition of individual patient’s airway inflammation. Inhaler technology will continue to innovate with ‘intelligent’ delivery systems allowing more precise targeting of specific areas of the lungs becoming more common. In addition, inhaler-based health monitoring devices providing feedback of inhaler use to patients and healthcare professionals offer the promise of improved treatment adherence and health outcomes."
Leading companies featured in the report include Aerocrine (Circassia), ALK-Abello A/S, Amphastar Pharmaceuticals, Inc., AstraZeneca, Boehringer Ingelheim, Chiesi Farmaceutici, Cipla, GlaxoSmithKline, Lallemand Pharma International, Merck, MundiPharma, Novartis and more.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to firstname.lastname@example.org or call her on +44 (0) 207 336 6100.
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
Nutraceuticals are the products that provide medicinal and health benefits to the people. These products provide additional nutritional value to the foodstuff.
01 June 2020
Visiongain anticipates that the global precision medicine market is projected to witness a CAGR of 12% over the forecast period from 2020 to 2030. The global precision medicine market is anticipated to surpass US$ 67 billion in 2020 and is further projected to surpass US$ 200 billion in 2030.
27 May 2020
The global colon targeting drug delivery market is projected to grow at a CAGR of 8.07% in the first half of the forecast period. Visiongain anticipate that the global market will witness a CAGR of 9.23% during the forecast period 2020 to 2030.
27 May 2020
The automation in biopharma industry market is estimated to grow at a CAGR of 4.3% over the forecast period.